New Self-Amplifying RNA vaccines show promise in early COVID-19 trial
NCT ID NCT05037097
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested three new self-amplifying RNA vaccines against COVID-19 in 72 healthy adults, some already vaccinated and some not. The goal was to check safety and how well the vaccines boost the immune system. Results help decide which vaccine candidates to study further.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONA VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Arcturus Investigational Site 101
Singapore, 169608, Singapore
-
Arcturus Investigational Site 201
Kansas City, Missouri, 64114, United States
-
Arcturus Investigational Site 202
Wichita, Kansas, 67207, United States
-
Arcturus Investigational Site 301
Diepkloof, Soweto, 1862, South Africa
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?